Plain-English translation of NCT07606014 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a probiotic formulation called Ecologic® Barrier can help prevent or reduce metabolic side effects—like weight gain, high blood sugar, and high cholesterol—that commonly occur when taking antipsychotic medications such as olanzapine, quetiapine, risperidone, or clozapine. The study is based on research suggesting that the bacteria in your gut may play a role in how your body manages weight and metabolism, and that adding beneficial bacteria through probiotics might help protect against these unwanted effects.
Antipsychotic medications are effective for treating serious mental health conditions, but they often cause metabolic problems that can lead to weight gain, diabetes, and heart disease. This trial exists to see whether probiotics—live beneficial bacteria—might help prevent or reduce these side effects and keep people healthier.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either the probiotic powder or a placebo (inactive powder) once daily for 12 weeks. Both look and taste the same, and neither you nor the researchers will know which group you're in. You will continue taking your antipsychotic medication as prescribed, and the research team will monitor your weight, blood sugar, and cholesterol levels to see if the probiotic helps prevent metabolic changes.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
Netherlands